You are here

Articles

"Treating Chronic Myeloid Leukemia Improving Management through understanding the patient experiences"

published: 17 June 2013

Landmark analysis of 4-year (y) data from ENESTnd.

published: 12 June 2013

Plasma trough imatinib levels and molecular response in patients with CML: A single institution study from India.

published: 12 June 2013

How I Manage: Chronic Myeloid Leukemia by Jerald Radich, MD

published: 5 June 2013

Targeting of the MNK–eIF4E axis in blast crisis CML inhibits leukemia stem cell function

published: 5 June 2013

population study shows the advent of 2ndGen TKIs has improved progression-free survival in CML

published: 1 June 2013

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

published: 12 May 2013

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

published: 12 May 2013

Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts

published: 26 April 2013

ESK1-New Monoclonal Antibody Targets Intracellular Oncogenic Proteins in Leukemias

published: 17 April 2013

Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?

published: 17 April 2013

Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib

published: 17 April 2013

Chronic Fatigue Limits Quality of Life in Imatinib-Treated CML Patients

published: 17 April 2013

Long-Term Treatment With Imatinib Affected Bone Mineral Density

published: 17 April 2013

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

published: 11 April 2013

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

published: 5 April 2013

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

published: 31 March 2013

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

published: 27 March 2013

Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

published: 27 March 2013

EMA approves marketing authorisation for ponatinib/Iclusig

published: 23 March 2013